Beam Therapeutics Inc. Basic Shares Outstanding (Weighted Average)
Beam Therapeutics Inc. (BEAM) reported Basic Shares Outstanding (Weighted Average) of 104.33 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-04
- Beam Therapeutics Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 104.33M shares, a 2.29% increase year-over-year.
- Beam Therapeutics Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 103.26M shares, a 17.38% increase year-over-year.
- Beam Therapeutics Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 102.92M shares, a 24.26% increase year-over-year.
- Beam Therapeutics Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 102.57M shares, a 24.46% increase year-over-year.
- Beam Therapeutics Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 98.91M shares, a 20.16% increase from fiscal 2024.
- Beam Therapeutics Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 82.31M shares, a 6.69% increase from fiscal 2023.
- Beam Therapeutics Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 77.15M shares, a 10.19% increase from fiscal 2022.
- Beam Therapeutics Inc. weighted average number of shares outstanding, basic for fiscal 2022 was 70.02M shares, a 9.01% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 104.33M shares 10-Q · filed 2026-08-04 | 103.80M shares 10-Q · filed 2026-08-04 | 103.50M shares derived: average of 3 quarters · filed 2026-08-04 | 103.27M shares derived: average of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | 103.26M shares 10-Q · filed 2026-05-07 | 103.09M shares derived: average of 2 quarters · filed 2026-05-07 | 102.92M shares derived: average of 3 quarters · filed 2026-05-07 | 102.69M shares derived: average of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | 102.92M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | 102.75M shares derived: average of 2 quarters · filed 2026-02-24 | 102.50M shares derived: average of 3 quarters · filed 2026-08-04 | 98.91M shares 10-K · filed 2026-02-24 |
| 2025-09-30 | 102.57M shares 10-Q · filed 2025-11-04 | 102.28M shares derived: average of 2 quarters · filed 2026-08-04 | 97.57M shares 10-Q · filed 2025-11-04 | 93.84M shares derived: average of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | 102.00M shares 10-Q · filed 2026-08-04 | 95.02M shares 10-Q · filed 2026-08-04 | 90.93M shares derived: average of 3 quarters · filed 2026-08-04 | 88.80M shares derived: average of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | 87.98M shares 10-Q · filed 2026-05-07 | 85.40M shares derived: average of 2 quarters · filed 2026-05-07 | 84.40M shares derived: average of 3 quarters · filed 2026-05-07 | 83.88M shares derived: average of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | 82.83M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | 82.62M shares derived: average of 2 quarters · filed 2026-02-24 | 82.52M shares derived: average of 3 quarters · filed 2026-02-24 | 82.31M shares 10-K · filed 2026-02-24 |
| 2024-09-30 | 82.41M shares 10-Q · filed 2025-11-04 | 82.36M shares derived: average of 2 quarters · filed 2025-11-04 | 82.14M shares 10-Q · filed 2025-11-04 | 81.83M shares derived: average of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | 82.31M shares 10-Q · filed 2025-08-05 | 82.01M shares 10-Q · filed 2025-08-05 | 81.64M shares derived: average of 3 quarters · filed 2026-02-24 | 80.98M shares derived: average of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | 81.70M shares 10-Q · filed 2025-05-06 | 81.30M shares derived: average of 2 quarters · filed 2026-02-24 | 80.54M shares derived: average of 3 quarters · filed 2026-02-24 | 79.49M shares derived: average of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | 80.90M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | 79.96M shares derived: average of 2 quarters · filed 2026-02-24 | 78.75M shares derived: average of 3 quarters · filed 2026-02-24 | 77.15M shares 10-K · filed 2026-02-24 |
| 2023-09-30 | 79.02M shares 10-Q · filed 2024-11-05 | 77.68M shares derived: average of 2 quarters · filed 2024-11-05 | 75.90M shares 10-Q · filed 2024-11-05 | 74.60M shares derived: average of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | 76.34M shares 10-Q · filed 2024-08-06 | 74.32M shares 10-Q · filed 2024-08-06 | 73.13M shares derived: average of 3 quarters · filed 2025-02-25 | 72.43M shares derived: average of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | 72.27M shares 10-Q · filed 2024-05-07 | 71.53M shares derived: average of 2 quarters · filed 2025-02-25 | 71.13M shares derived: average of 3 quarters · filed 2025-02-25 | 70.90M shares derived: average of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | 70.79M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | 70.56M shares derived: average of 2 quarters · filed 2025-02-25 | 70.45M shares derived: average of 3 quarters · filed 2025-02-25 | 70.02M shares 10-K · filed 2025-02-25 |
| 2022-09-30 | 70.34M shares 10-Q · filed 2023-11-08 | 70.28M shares derived: average of 2 quarters · filed 2023-11-08 | 69.76M shares 10-Q · filed 2023-11-08 | 69.32M shares derived: average of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | 70.21M shares 10-Q · filed 2023-08-08 | 69.46M shares 10-Q · filed 2023-08-08 | 68.98M shares derived: average of 3 quarters · filed 2024-02-27 | 68.33M shares derived: average of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | 68.70M shares 10-Q · filed 2023-05-10 | 68.37M shares derived: average of 2 quarters · filed 2024-02-27 | 67.70M shares derived: average of 3 quarters · filed 2024-02-27 | 66.33M shares derived: average of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | 68.03M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | 67.20M shares derived: average of 2 quarters · filed 2024-02-27 | 65.54M shares derived: average of 3 quarters · filed 2024-02-27 | 64.23M shares 10-K · filed 2024-02-27 |
| 2021-09-30 | 66.38M shares 10-Q · filed 2022-11-07 | 64.29M shares derived: average of 2 quarters · filed 2022-11-07 | 62.96M shares 10-Q · filed 2022-11-07 | 61.35M shares derived: average of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | 62.21M shares 10-Q · filed 2022-08-09 | 61.22M shares 10-Q · filed 2022-08-09 | 59.68M shares derived: average of 3 quarters · filed 2023-02-28 | 57.28M shares derived: average of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | 60.21M shares 10-Q · filed 2022-05-09 | 58.41M shares derived: average of 2 quarters · filed 2023-02-28 | 55.64M shares derived: average of 3 quarters · filed 2023-02-28 | 54.09M shares derived: average of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | 56.62M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | 53.35M shares derived: average of 2 quarters · filed 2023-02-28 | 52.04M shares derived: average of 3 quarters · filed 2023-02-28 | 46.73M shares 10-K · filed 2023-02-28 |
| 2020-09-30 | 50.09M shares 10-Q · filed 2021-11-08 | 49.76M shares derived: average of 2 quarters · filed 2021-11-08 | 43.44M shares 10-Q · filed 2021-11-08 | |
| 2020-06-30 | 49.43M shares 10-Q · filed 2021-08-10 | 40.08M shares 10-Q · filed 2021-08-10 | ||
| 2019-12-31 | 6.48M shares 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |